Analysts who follow Eiger Biopharmaceuticals Inc (EIGR) on average expect it to increase 389.13% over the next twelve months. Those same analysts give the stock an average rating of Strong Buy. That average rating earns the stock an Analyst Ranking of 75, which means it ranks higher than 75 of stocks, based on data compiled by InvestorsObserver.
Wall Street analysts are rating EIGR a Strong Buy today. Find out what this means to you and get the rest of the rankings on EIGR!